Basel, January 4, 2022 Today, Novartis announced that the U.S. Court of Appeals for the Federal Circuit (CAFC) issued its decision upholding the validity.
Novartis announces U.S. Court of Appeals for the Federal Circuit (CAFC) upholds validity of Gilenya® (fingolimod) dosage regimen patent novartis.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from novartis.com Daily Mail and Mail on Sunday newspapers.
Novartis announces positive results from year two of the Phase III trial of Beovu® in diabetic macular edema novartis.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from novartis.com Daily Mail and Mail on Sunday newspapers.